Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Canaccord Genuity Growth Conference (Virtual) Transcript

Aug 11, 2021 / 12:00PM GMT
Release Date Price: €35.69 (-0.97%)
Sumant Satchidanand Kulkarni
Canaccord Genuity Corp., Research Division - Analyst

Good day, everyone. I'm Sumant Kulkarni, a senior biotechnology analyst at Canaccord Genuity, and I'm pleased to welcome you all to our growth conference this year. Hope all of you are staying safe and enjoying your summer so far.

I'm pleased to have Sage Therapeutics with us at a very interesting time for the company. For Sage, we have CEO, Barry Greene. We'll be keeping this very interactive. So please feel free to send questions to me using your web-based interface or e-mail me at [email protected].

And with that, I'll turn it over to Barry, or we can just go straight to Q&A, depending on how he'd like to go.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Yes. Sumant, thanks for having us, and I'd like to thank the organizers for Canaccord for having us here. It's very -- as you said, it's a very exciting time for Sage. We have had a very catalyst-rich year. We see ourselves as leaders in brain health and believe that we could

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot